RU2358735C2 - Агонисты м1 мускариновых рецепторов для противоболевой терапии - Google Patents

Агонисты м1 мускариновых рецепторов для противоболевой терапии Download PDF

Info

Publication number
RU2358735C2
RU2358735C2 RU2005133197/14A RU2005133197A RU2358735C2 RU 2358735 C2 RU2358735 C2 RU 2358735C2 RU 2005133197/14 A RU2005133197/14 A RU 2005133197/14A RU 2005133197 A RU2005133197 A RU 2005133197A RU 2358735 C2 RU2358735 C2 RU 2358735C2
Authority
RU
Russia
Prior art keywords
optionally substituted
alkyl
group
aryl
alkynyl
Prior art date
Application number
RU2005133197/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2005133197A (ru
Inventor
Роберт Р. ДЭВИС (US)
Роберт Р. ДЭВИС
Кимберли ВАНОВЕР (US)
Кимберли ВАНОВЕР
Марио РОДРИГЕС (US)
Марио РОДРИГЕС
Original Assignee
Акадиа Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акадиа Фармасьютикалз Инк. filed Critical Акадиа Фармасьютикалз Инк.
Publication of RU2005133197A publication Critical patent/RU2005133197A/ru
Application granted granted Critical
Publication of RU2358735C2 publication Critical patent/RU2358735C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2005133197/14A 2003-03-28 2004-03-26 Агонисты м1 мускариновых рецепторов для противоболевой терапии RU2358735C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45904503P 2003-03-28 2003-03-28
US60/459,045 2003-03-28

Publications (2)

Publication Number Publication Date
RU2005133197A RU2005133197A (ru) 2006-04-27
RU2358735C2 true RU2358735C2 (ru) 2009-06-20

Family

ID=33131858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005133197/14A RU2358735C2 (ru) 2003-03-28 2004-03-26 Агонисты м1 мускариновых рецепторов для противоболевой терапии

Country Status (13)

Country Link
US (1) US20050130961A1 (enExample)
EP (1) EP1613321A2 (enExample)
JP (1) JP2006521399A (enExample)
KR (1) KR20050112116A (enExample)
CN (1) CN1777425A (enExample)
AU (1) AU2004226430A1 (enExample)
BR (1) BRPI0409523A (enExample)
CA (1) CA2520125A1 (enExample)
MX (1) MXPA05010171A (enExample)
NZ (1) NZ542690A (enExample)
RU (1) RU2358735C2 (enExample)
WO (1) WO2004087158A2 (enExample)
ZA (1) ZA200508733B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162616A0 (en) * 2001-12-28 2005-11-20 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
KR20070036149A (ko) * 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 이량체 피페리딘 유도체
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009094459A1 (en) 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
RU2015144155A (ru) * 2013-03-15 2017-04-24 Акадиа Фармасьютикалз Инк. Мускариновые агонисты
CN106536508B (zh) 2014-04-23 2019-08-09 武田药品工业株式会社 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物
CR20170568A (es) 2015-06-26 2018-04-20 Takeda Pharmaceuticals Co Compuesto heterocíclico
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US20220144817A1 (en) * 2019-02-22 2022-05-12 Karuna Therapeutics, Inc. Compounds and methods of deuterated xanomeline for treating neurological disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2160098C2 (ru) * 1996-04-05 2000-12-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Применение бензонафталиновых производных для получения лекарственных средств, предназначенных для лечения заболеваний нервной системы
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5155166A (en) * 1990-06-18 1992-10-13 Eastman Kodak Company Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
GB2292685A (en) * 1994-07-27 1996-03-06 Sankyo Co Allosteric effectors at muscarinic receptors
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
WO2000030632A1 (en) * 1998-11-23 2000-06-02 Eisai Co., Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
TWI310034B (en) * 2001-10-02 2009-05-21 Acadia Pharmaceuticais Inc Benzimidazolidinone derivatives as muscarinic agents
IL162616A0 (en) * 2001-12-28 2005-11-20 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
RU2160098C2 (ru) * 1996-04-05 2000-12-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Применение бензонафталиновых производных для получения лекарственных средств, предназначенных для лечения заболеваний нервной системы
WO2001083472A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HWANG J.H. et al. The antiallodynic effects of intrathecal cholinesterase inhibitors in a rat model of neuropathic pain. Anesthesiology. 1999 Feb; 90(2):492-9, реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 29.12.2007], PMID: 9952157 [PubMed - indexed for MEDLINE]. GHELARDINI С. et al. Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology. 2002 Dec; 43(7):1180-7. реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 29.12.2007], PMID: 12504925 [PubMed - indexed for MEDLINE]. OBATA H. et al. Possible involvement of a muscarinic receptor in the anti-allodynic action of a 5-HT2 receptor agonist in rats with nerve ligation injury. Brain Res. 2002 Apr.5; 932(1-2):124-8. реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 29.12.2007], PMID: 11911869 [PubMed - indexed for MEDLINE]. *

Also Published As

Publication number Publication date
WO2004087158A3 (en) 2005-03-31
US20050130961A1 (en) 2005-06-16
RU2005133197A (ru) 2006-04-27
JP2006521399A (ja) 2006-09-21
NZ542690A (en) 2009-04-30
WO2004087158A2 (en) 2004-10-14
CA2520125A1 (en) 2004-10-14
EP1613321A2 (en) 2006-01-11
MXPA05010171A (es) 2005-12-12
AU2004226430A1 (en) 2004-10-14
CN1777425A (zh) 2006-05-24
BRPI0409523A (pt) 2006-04-18
KR20050112116A (ko) 2005-11-29
ZA200508733B (en) 2006-09-27

Similar Documents

Publication Publication Date Title
RU2358735C2 (ru) Агонисты м1 мускариновых рецепторов для противоболевой терапии
EP1045693B1 (en) Aminophenoxyacetic acid derivatives as neuroprotectants
JP3553083B2 (ja) 末梢性活性抗痛覚過敏オピエート
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
JP6528779B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
EP1100495A1 (en) Propenamides as ccr5 modulators
IL118328A (en) Use of a combination of a forebrain selective N-methyl-D-aspartate antagonist and excitatory feedback enhancing agent in the preparation of pharmaceutical composition for treating Parkinson's disease
WO2002005819A1 (en) Compounds and methods
EP0627221A2 (en) Substance P antagonists for the treatment of emesis
RU2333200C2 (ru) Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
WO2001064213A1 (en) Compounds and methods
WO2002058687A2 (en) Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
CA2250856A1 (en) Treatment of mood/affective disorders by glutamatergic upmodulators
EP1687641A2 (en) Treating neuropathic pain with neuropeptide ff receptor 2 agonists
AU779152B2 (en) Prophylactic use of N-methyl-D-aspartate (NMDA) antagonists
JP2000309545A (ja) 愛玩動物の年齢関連行動障害治療方法および治療用組成物
US20020193380A1 (en) Method for treatment of pain
EP0655246A1 (en) Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
EP0659409A2 (en) Substance 1 antagonists for the inhibition of angiogenesis
AU2018215466A1 (en) Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof
JPH07503240A (ja) ３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用
CN101014570A (zh) 吡啶衍生物或其药学上可接受的盐